Overview

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Bucci Laser Vision Institute
Frank A. Bucci, Jr., M.D.
Treatments:
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Besifloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination